Overview of the Role of 308 Monochromatic Excimer Phototherapy for the Treatment of Alopecia Areata

December 2022 in “ IntechOpen eBooks ”

Nabeel K. Al Hamzawi, Mohammed S. Al Baaj

308 monochromatic excimer phototherapy Alopecia Areata UVB light apoptosis T cells moderate-to-severe AA clinical response whole-body phototherapy 308 excimer phototherapy AA UVB

Studysummary This source evaluates the clinical effectiveness of 308 nm monochromatic excimer phototherapy in treating moderate-to-severe alopecia areata, noting that both laser and lamp methods show promise without significant risks.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document discusses the use of 308 monochromatic excimer phototherapy for treating Alopecia Areata (AA), a hair loss condition. This therapy, which uses a UVB light source, works by inducing apoptosis in T cells and has been successful in treating both adults and children with moderate-to-severe AA. The document reviews various studies with different participant numbers, generally concluding that the therapy is safe and effective, though results can vary. The treatment protocol involves administering the therapy one or two times per week until a clinical response is observed, with the treatment continuing for 12 weeks (24 sessions). The document concludes that 308 excimer phototherapy is a safe and effective treatment for AA, requiring a shorter treatment duration than whole-body phototherapy.

View this study on intechopen.com →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

Combining 308-Monochromatic Excimer Phototherapy with Monthly IM Triamcinolone Acetonide for the Treatment of Resistant Alopecia Totalis

research Combining 308-Monochromatic Excimer Phototherapy with Monthly IM Triamcinolone Acetonide for the Treatment of Resistant Alopecia Totalis

2 citations , December 2020 in “American Journal of Dermatological Research and Reviews”

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

86 citations , January 2020 in “British Journal of Dermatology”

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

research Efficacy and Influence Factors of 308-nm Excimer Lamp with Minoxidil in the Treatment of Alopecia Areata

4 citations , January 2020 in “Lasers in Surgery and Medicine”

This study found that combining a 308-nm excimer lamp with minoxidil led to significant hair regrowth in alopecia areata patients, with side effects like hyperpigmentation being tolerable.

research Pathomechanisms of Immune-Mediated Alopecia

45 citations , April 2019 in “International Immunology”

This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.

research Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management

102 citations , December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

research Treating Alopecia Areata: Current Practices Versus New Directions

26 citations , October 2016 in “American journal of clinical dermatology”

New treatments like JAK inhibitors show promise for reversing alopecia areata.

research Phototherapy for Alopecia Areata

9 citations , May 2016 in “Clinics in dermatology”

This article reviews the use of phototherapy for alopecia areata and highlights its potential due to the therapy's modulatory effects on the skin's immune system, but it presents no new research findings.

research 308-Nanometer Excimer Light Therapy for Alopecia Universalis Resistant to Other Treatments: A Clinical Study of 11 Patients

13 citations , April 2016 in “Journal of Dermatology”

In this study, 308-nm excimer light therapy showed significant effects in some patients with treatment-resistant alopecia universalis, suggesting it as a potential alternative therapy.

research Effectiveness of 308-nm Excimer Laser Therapy in Treating Alopecia Areata by Examining Treated Sides of Selected Alopecic Patches

30 citations , January 2015 in “Dermatology”

This study found that 308-nm excimer laser therapy improved hair diameter in alopecia areata patients, as shown by photographic assessments and a side-by-side comparison with control patches.

research Excimer Lamp as an Effective Alternative Treatment for Severe Alopecia Areata

4 citations , December 2014 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì”

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

research Alopecia Areata Update

85 citations , October 2012 in “Dermatologic Clinics”

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

research 308-Nm Excimer Laser Therapy in Alopecia Areata

85 citations , November 2004 in “Journal of the American Academy of Dermatology”

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.